<DOC>
	<DOCNO>NCT01431898</DOCNO>
	<brief_summary>This research study evaluate safety , tolerability anti-viral activity GS-9669 patient Hepatitis C infection .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Antiviral Activity GS-9669 Subjects With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Adult subject 1865 year old , inclusive Documented chronic HCV infection least 6 month duration plasma HCV RNA ≥ 5 log10 IU/mL screening . HCV treatment naïve PEGIFN , IFN , and/or RBV experience ( treatment must cease least 3 month prior screen ) . Treatment experienced subject exceed 40 % subject enrol cohort Monoinfection HCV genotype 1a Cohorts 1 , 2 , 3 , 4 , 5 monoinfection HCV genotype 1b Cohort 6 7 . Estimated creatinine clearance ≥ 70 mL/min , QTcF interval ≤ 450 msec male ≤ 470 msec female , QRS duration &lt; 120 msec , PR interval &lt; 220 msec , Body mass index ( BMI ) 19.0 34.0 kg/m^2 , inclusive . Urine drug screen positive illicit/illegal drug ALT AST level &gt; 5 time upper limit normal range ( ULN ) Direct bilirubin &gt; ULN , clinical laboratory evidence hepatic decompensation ( i.e. , platelet &lt; 90,000/mm^3 , prothrombin time ≥ 1.5 × ULN albumin &lt; 3.5 g/dL ) eligible study participation . Subjects absolute neutrophil count ( ANC ) &lt; 1,000 cells/mm^3 ( &lt; 750 cells/mm^3 black AfricanAmerican subject ) , hemoglobin ( Hb ) &lt; 11 g/dL , Coinfected hepatitis B virus ( HBV ) , human immunodeficiency virus ( HIV ) , another HCV genotype genotype 1a/b eligible study participation . Evidence hepatocellular carcinoma ( e.g. , afetoprotein &gt; 50 ng/mL indicated recent ultrasound standard care measure ) History significant cardiac disease . The following ECG abnormality screen exclusionary : QTcF ( QT correct use Fridericia 's formula=QT/RR^0.333 ) &gt; 450 msec male &gt; 470 female ; QRS &gt; 120 msec ( left right hemiblock exclusionary ) ; PR interval &gt; 220 msec ; bradycardia ( &lt; 45 beat per minute ) ; second third degree heart block . History clinicallysignificant illness major medical disorder may interfere subject treatment , assessment compliance protocol History primary gastrointestinal disorder could interfere absorption study drug could interfere normal gastrointestinal anatomy motility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HCV RNA</keyword>
	<keyword>Polymerase inhibitor</keyword>
	<keyword>Treatment naïve Treatment experience</keyword>
	<keyword>GS-9669</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
</DOC>